Business
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of the Company’s novel oncolytic peptide, V
About this update from Verrica Pharmaceuticals Inc.
[{"type":"image","alt":"Verrica Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Verrica Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":268,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y2cneuDnn4HyXuHz4iGLdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Mw--/https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b","width":268,"height":117}},"lazy":false},{"type":"text","content":"Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors ","length":109,"tagName":"p"},{"type":"text","content":"WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of the Company’s novel oncolytic peptide, VP-315 (ruxotemitide), in the treatment of basal cell carcinoma (BCC) at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, taking place from May 13-16, 2026, in Chicago, Illinois. Patients with BCC frequently present with multiple tumors, and approximately one-third will develop additional primary tumors over their lifetime, highlighting the need for therapies that address diseases such as BCC with multifocal potential.","length":831,"tagName":"p"},{"type":"text","content":"“The peripheral anticancer activity we are observing well beyond the injection site suggests that VP-315 could be exerting an abscopal effect for the treatment of basal cell carcinoma,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. “Such activity may indicate a broader immune activation within the tumor microenvironment of non-target lesions. If this is demonstrated in further pivotal testing, it could suggest that VP-315 has a unique potential to not only effectively treat primary BCC lesions but could also address the unmet need in patients with more than one lesion. It could also benefit patients with difficult to detect, residual disease that can sometimes be left behind after surgical excision of the tumor,”...